Table 1: Description of the clinical characteristics of Group I: 26 patients submitted to HSCT.
|
Clinical Parameters |
N = 26 (100%) |
|
Gender |
|
|
Male |
16 (61%) |
|
Female |
10 (39%) |
|
Age (years) Median: 36 (range 18-65) |
|
|
18 a 50 |
19 (73%) |
|
≥ 50 |
7 (27%) |
|
Diagnosis |
|
|
AML, ALL, SMD |
15 (61%) |
|
LH, LNH |
7 (27%) |
|
CML |
1 (3.8%) |
|
MM |
1 (3.8%) |
|
AA |
2 (7.6%) |
|
Donor Type |
|
|
Related |
20 (76.9%) |
|
Non Related |
6 (23.1%) |
|
HLA Match |
|
|
10/10 |
23 (88.5%) |
|
09/10 (misA) |
1 (3.8%) |
|
Haplo |
2 (7.7%) |
|
Conditioning Regimen |
|
|
Myeloablative |
16 (61.5%) |
|
Reduced Intensity Conditioning |
10 (38.5%) |
|
Prophilaxis of GVHD |
|
|
CSA + MTX |
22 (85.6%) |
|
CSA + MMF |
4 (15.4%) |
|
Disease status pre transplant |
|
|
1a CR (First Complete Remission) |
9 (34.6%) |
|
2a CR (Second Complete Remission) |
2 (7.7%) |
|
3a CR (Third Complete Remission) |
3 (11.5%) |
|
No remission |
10 (38.5%) |
|
Bone Marrow Aplasia |
2 (7.7%) |
|
Source of Stem Cell |
|
|
Peripheral blood (PB) |
17 (65%) |
|
Bone Morrow (BM) |
9 (35%) |
AML: Acute Myelogenous Leukemia; ALL: Acute Lymphoblastic Leukemia; MS: Myelodysplastic Syndromes; HL: Hodgkin's Lymphoma; NHL: Non-Hodgkin's Lymphoma; CML: Chronic Myelogeneous Leukemia; MM: Multiple Myeloma; AA: Aplastic Anemia; Bu: Busulphan; Cy: Cyclophosphamida; TBI: Total Body Irradiation; ATG: Anti-Thymoglobulin; Flu: Fludarabina; Mel: Melphalan; CSA: Cyclosporin; MTX: Methotrexate; SM: Sodium Mycophelonate; aGVHD: Acute Graft Versus Host Disease.